ES2180730T3 - Uso de nucleosidos sustituidos en 5 para inhibir la formacion de resistencias en el tratamiento con citostaticos. - Google Patents

Uso de nucleosidos sustituidos en 5 para inhibir la formacion de resistencias en el tratamiento con citostaticos.

Info

Publication number
ES2180730T3
ES2180730T3 ES96901696T ES96901696T ES2180730T3 ES 2180730 T3 ES2180730 T3 ES 2180730T3 ES 96901696 T ES96901696 T ES 96901696T ES 96901696 T ES96901696 T ES 96901696T ES 2180730 T3 ES2180730 T3 ES 2180730T3
Authority
ES
Spain
Prior art keywords
treatment
bvdu
citostatics
nucleosids
resistors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96901696T
Other languages
English (en)
Inventor
Rudolf Fahrig
Angela Dr Steinkamp-Zucht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RESprotect GmbH
Original Assignee
RESprotect GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19545892A external-priority patent/DE19545892A1/de
Application filed by RESprotect GmbH filed Critical RESprotect GmbH
Application granted granted Critical
Publication of ES2180730T3 publication Critical patent/ES2180730T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

LA INVENCION TRATA DE LA UTILIZACION DE NUCLEOSIDOS 5''SUSTITUIDOS EN COMBINACION CON AL MENOS UN CITOSTATICO, PARA LA FABRICACION DE UN MEDICAMENTO QUE IMPIDA O REDUZCA LA RESISTENCIA EN EL TRATAMIENTO CITOSTATICO, ASI COMO DE UN MEDICAMENTO QUE CONTIENE BVDU Y/O SUS METABOLITOS.
ES96901696T 1995-02-01 1996-01-31 Uso de nucleosidos sustituidos en 5 para inhibir la formacion de resistencias en el tratamiento con citostaticos. Expired - Lifetime ES2180730T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19503152 1995-02-01
DE19545892A DE19545892A1 (de) 1995-12-08 1995-12-08 Verwendung von (E)-5-(2-Bromovinyl-)-2'-deoxyuridine (BVDU) zur Resistenzbildung bei der Zytostatikabehandlung und Arzneimittel, enthaltend BVDU

Publications (1)

Publication Number Publication Date
ES2180730T3 true ES2180730T3 (es) 2003-02-16

Family

ID=26012025

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96901696T Expired - Lifetime ES2180730T3 (es) 1995-02-01 1996-01-31 Uso de nucleosidos sustituidos en 5 para inhibir la formacion de resistencias en el tratamiento con citostaticos.

Country Status (12)

Country Link
US (1) US6589941B1 (es)
EP (1) EP0806956B1 (es)
JP (1) JPH11502515A (es)
KR (1) KR100330602B1 (es)
AT (1) ATE222765T1 (es)
BR (1) BR9607109A (es)
DE (1) DE59609590D1 (es)
DK (1) DK0806956T3 (es)
ES (1) ES2180730T3 (es)
NO (1) NO315258B1 (es)
PT (1) PT806956E (es)
WO (1) WO1996023506A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69840216D1 (de) * 1997-08-08 2008-12-24 Celmed Oncology Usa Inc Verfahren und Zubereitungen um Resistenz gegen biologische oder chemische Therapien zu Überwinden
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
PT1045897E (pt) 1998-01-23 2002-07-31 Newbiotics Inc Agentes terapeuticos por catalise enzimatica
DE19842578A1 (de) * 1998-09-17 2000-03-23 Max Delbrueck Centrum Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zum Herabsetzen thrombocytopenischer Nebenwirkungen von Cytostatika
EP1200130A2 (en) 1999-07-22 2002-05-02 Newbiotics, Inc. Methods for treating therapy-resistant tumors
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
AU2451601A (en) * 1999-12-23 2001-07-03 Newbiotics, Inc. Use of bvdu for inhibiting the growth of hyperproliferative cells
US20030212037A1 (en) * 2000-12-21 2003-11-13 Christopher Boyer Use of bvdu for inhibiting the growth of hyperproliferative cells
CA2441350A1 (en) 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
DE10313035A1 (de) * 2003-03-24 2004-10-07 Resprotect Gmbh Methode zur Verstärkung der apoptotischen Wirkung von Zytostatika ohne Erhöhung toxischer Nebenwirkungen
US20060269596A1 (en) * 2005-01-12 2006-11-30 Gary Liversidge Controlled release compositions comprising an acylanilide
HUP0600042A3 (en) * 2006-01-19 2012-12-28 Debreceni Egyetem New medical use of thiolated pyrimidine-mononucleotides and -nucleosides
DE102006037786A1 (de) * 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US20090068286A1 (en) * 2007-09-11 2009-03-12 Resprotect, Gmbh Method of treating cancer by administration of 5-substituted nucleosides
EP2135601A1 (en) * 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilization of amorphous drugs using sponge-like carrier matrices
DE102008030091B4 (de) 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
CN103209987B (zh) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
SI2709613T2 (sl) 2011-09-16 2020-12-31 Gilead Pharmasset LLC c/o Gilead Sciences, Inc. Postopki za zdravljenje HCV
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
WO2013142124A1 (en) 2012-03-21 2013-09-26 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (en) 2012-03-22 2015-10-28 Alios Biopharma Inc PHARMACEUTICAL COMBINATIONS WITH A THIONUCLEOTIDE ANALOG
SG11201506021XA (en) 2013-01-31 2015-08-28 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1069096A (en) * 1962-11-23 1967-05-17 Ile De Rech S Scient Et Ind So New organic derivatives of nucleotides and method for their manufacture
GB1473148A (es) * 1974-09-16 1977-05-11
US4902678A (en) * 1982-02-12 1990-02-20 Syntex (U.S.A.) Inc. Anti-viral compositions
NL8700366A (nl) * 1987-02-13 1988-09-01 Stichting Rega V Z W Combinatie van fu met bvdu als middel tegen adenocarcinoom.
US5250296A (en) * 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US5831064A (en) 1996-07-25 1998-11-03 The Trustees Of Columbia University In The City Of New York Kaposi's sarcoma-associated herpes virus (KSHV) interferon consensus sequence binding protein (ICSBP) and uses thereof
PT1045897E (pt) 1998-01-23 2002-07-31 Newbiotics Inc Agentes terapeuticos por catalise enzimatica

Also Published As

Publication number Publication date
KR19980701862A (ko) 1998-06-25
US6589941B1 (en) 2003-07-08
MX9705758A (es) 1997-10-31
ATE222765T1 (de) 2002-09-15
PT806956E (pt) 2003-01-31
EP0806956A1 (de) 1997-11-19
DK0806956T3 (da) 2003-01-06
EP0806956B1 (de) 2002-08-28
NO315258B1 (no) 2003-08-11
WO1996023506A1 (de) 1996-08-08
BR9607109A (pt) 1997-11-04
DE59609590D1 (de) 2002-10-02
JPH11502515A (ja) 1999-03-02
KR100330602B1 (ko) 2002-08-22
NO973529L (no) 1997-10-01
NO973529D0 (no) 1997-07-31

Similar Documents

Publication Publication Date Title
ES2180730T3 (es) Uso de nucleosidos sustituidos en 5 para inhibir la formacion de resistencias en el tratamiento con citostaticos.
DE3587434D1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
EP2295063A8 (en) Compositions and the use thereof the treatment of mitochondrial diseases
CA2103458A1 (en) Method and composition to reduce myocardial reperfusion injury
BR9904719A (pt) Composição para incrementar a permeabilidade de agentes tópicos à pele
BG103740A (en) Phytostyrene composition for the prevention of the alzheimer's disease
PL309348A1 (en) Application of an agent called riluzole in therapy of neurological damages caused by or associated with injuries
CA2225808A1 (en) Silver-based pharmaceutical compositions
BR9808948A (pt) Composição de confeitaria
CA2158475A1 (en) Composition and method for reducing toxicity of biologically-active factors
ES2177642T3 (es) Uso de ciertos derivados de acido metanobisfosfonico para prevenir el desprendimiento y la migracion de protesis.
BR9507073A (pt) Composto processos para preparar o mesmo e para tratar uma doença no sistema nervoso central composiçao farmacêutica e uso do composto
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
CA2339835A1 (en) Use of estrogenic compounds as anti-fungal agents
IL117874A0 (en) Pharmaceutical compositions for inhibiting the growth of viruses and cancers
CA2132544A1 (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
UA27221C2 (uk) Ефіри циклогексеноноксиму та гербіцидний засіб
BR9710957A (pt) Composição compreendendo um inibidor de canal katp uso no tratamento hemorrágico
UA29473C2 (uk) Фунгіцидна композиція, спосіб боротьби з фітопатогенними грибами
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
GR3034142T3 (en) Composition for the treatment or prevention of herpes
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
ATE289506T1 (de) Hemmung der tnf-aktivität mit zusammensetzungen enthaltend heparin und lösliche tnf rezeptoren
CO4940453A1 (es) Nuevo metodo de tratamiento con agente antihiperglucemicos inhibidores de alfaglucosida- sa para tratamiento de diabetes
GB9802542D0 (en) New use